Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
Oruka Therapeutics (Nasdaq: ORKA), a clinical stage biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, will present at the Bank of America Securities 2025 Health Care Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oruka Therapeutics (Nasdaq: ORKA), a clinical stage biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, will present at the Bank of America Securities 2025 Health Care Conference.
The presentation is scheduled for Tuesday, May 13th, 2025, at 3:55 PM PT. The company, based in Menlo Park, California, is working to establish new treatment standards in dermatology.
Positive
- Company is developing novel biologics for chronic skin diseases including plaque psoriasis
- Clinical stage status indicates progress in drug development pipeline
- Selected to present at a major healthcare conference, indicating industry recognition
Negative
- None.
Details
News Market Reaction – ORKA
The recorded move for ORKA in the trading session of this news was +1.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, 2025, at 3:55 PM PT.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.